MISSION
Mirum Pharmaceuticals is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. We are passionate about advancing scientific discoveries to become important medicines for rare disease patients. We are collaborative, creative, and experienced professionals and we’re looking to augment our team with other individuals who embody our values: care, be real, get it done, and have fun, seriously.
POSITION SUMMARY
Reporting to the SVP of Corporate Development and Strategy, the Senior Director, New Product Planning will help shape the company’s future portfolio by leading commercial strategy for pipeline assets, identifying lifecycle opportunities, evaluating external innovation, and helping define new areas for growth.
This individual will serve as the commercial strategy lead for pre-Phase 3 programs and partner closely with Research, Clinical Development, Medical Affairs, US and International Commercial, Business Development, Corporate Strategy, and Finance to integrate scientific, clinical, commercial, and financial perspectives into key development and investment decisions.
The ideal candidate combines scientific depth with strong commercial judgment and strategic and financial acumen. A core aspect of the role is connecting science with strategy— to identify new indications, evaluate portfolio opportunities, and shape clinical development and investment decisions to align with unmet need, competitive landscape, and strategic value drivers.
JOB FUNCTIONS/RESPONSIBILITIES
Business Development & External Innovation
- Lead commercial assessments of licensing, acquisition, and partnership opportunities, integrating scientific rationale, unmet need, clinical profile, competitive landscape, commercial potential, pricing and market access, and strategic fit.
- Conduct primary and secondary market research to develop patient-based forecasts, scenario analyses, and risk-adjusted valuations to support investment and transaction decisions.
- Partner with Business Development, R&D, Finance, and US and Global Commercial throughout opportunity evaluation and diligence.
Pipeline & Lifecycle Strategy
- Serve as the commercial strategy lead on cross-functional product teams for pre-Phase 3 pipeline programs before transition
- Develop business cases and commercial strategies for pipeline assets, including indication prioritization, Target Product Profiles, patient segmentation, value story, competitive differentiation, market opportunity, and lifecycle planning.
- Partner with Research, Clinical Development, Market Access, and Medical Affairs to incorporate commercial considerations into development strategy, including patient populations, endpoints, comparators, and real-world / health economic evidence generation.
- Partner with US and Global Commercial leaders to incorporate perspectives from key markets and ensure effective transition of assets into late-stage commercial planning.
Portfolio & Corporate Strategy
- Evaluate new therapeutic areas and disease spaces by integrating disease biology, unmet need, competitive dynamics, development feasibility, and commercial potential.
- Shape portfolio and corporate strategy by identifying growth opportunities, strategic gaps, and priorities for investment and resource allocation.
- Own commercial assumptions that inform long range planning for all pre-Ph3 programs
- Monitor scientific, clinical, competitive, regulatory, and market developments and translate them into implications for product and portfolio strategy.
QUALIFICATIONS
Education /Experience:
- 10+ years of experience in the biotechnology or pharmaceutical industry, including significant experience in New Product Planning, Commercial Strategy, Portfolio Strategy, Business Development, Business Analytics, Marketing / Market Access, or related roles.
- Strong scientific acumen and demonstrated ability to understand disease biology, molecular pathways, mechanisms of action, and clinical data and translate them into commercial and development strategy.
- Experience shaping strategy for pipeline assets, preferably during early and mid-stage clinical development.
- Experience evaluating new indications, lifecycle opportunities, new therapeutic areas, and/or external innovation opportunities.
- Strong experience with commercial forecasting, primary and secondary market research, business cases, and asset valuation.
- Demonstrated ability to influence senior leaders and cross-functional teams without direct authority.
- Communicate complex scientific, clinical, and commercial concepts effectively to scientific experts and senior executives.
Preferred
- PhD or MD strongly preferred; other advanced scientific or medical degrees with relevant experience will be considered.
- Experience in rare disease and/or specialty therapeutics.
- Experience collaborating with global commercial teams and working across multiple therapeutic areas.
- Experience supporting licensing, acquisition, or other business development transactions.
- Experience presenting strategic recommendations to Executive Leadership and governance committees.
Key Competencies
- Scientific & Clinical Acumen
- Commercial & Product Strategy
- Pipeline & Lifecycle Strategy
- Forecasting & Valuation
- Business Development Assessment
- Portfolio & Corporate Strategy
- Strategic Decision-Making
- Cross-Functional Leadership
- Executive Communication
The salary range for this position is $280,000 to $315,000 USD. Compensation will be determined based on several factors including, but not limited to; skill set, years of experience, and the employee’s geographic location. Please note that the required compensation details listed in US role postings reflect the base salary only, and do not include bonus, equity, or benefits unless otherwise provided.
#LI-HYBRID
Mirum Pharmaceuticals is committed to Equal Employment Opportunity (EEO) and to compliance with all Federal, State and Local laws that prohibit employment discrimination on the basis of race, age, national origin, ethnicity, religion, gender, gender identity, pregnancy, marital status, sexual orientation, citizenship, genetic disposition or characteristics, disability, veteran’s status or any other classification protected by applicable State/Federal/Local laws.
Mirum Pharmaceuticals provides reasonable accommodation for qualified individuals with disabilities and disabled veterans in job application procedures.
Skills Required
- 10+ years of experience in the biotechnology or pharmaceutical industry, including significant experience in New Product Planning, Commercial Strategy, Portfolio Strategy, Business Development, Business Analytics, Marketing, Market Access, or related roles.
- Strong scientific acumen and ability to understand disease biology, molecular pathways, mechanisms of action, and clinical data and translate them into commercial and development strategy.
- Experience shaping strategy for pipeline assets, preferably during early and mid-stage clinical development.
- Experience evaluating new indications, lifecycle opportunities, new therapeutic areas, and/or external innovation opportunities.
- Strong experience with commercial forecasting, primary and secondary market research, business cases, and asset valuation.
- Demonstrated ability to influence senior leaders and cross-functional teams without direct authority.
- Ability to communicate complex scientific, clinical, and commercial concepts effectively to scientific experts and senior executives.
- PhD or MD strongly preferred; other advanced scientific or medical degrees with relevant experience will be considered.
- Experience in rare disease and/or specialty therapeutics.
- Experience collaborating with global commercial teams and working across multiple therapeutic areas.
- Experience supporting licensing, acquisition, or other business development transactions.
- Experience presenting strategic recommendations to Executive Leadership and governance committees.
Mirum Pharmaceuticals Compensation & Benefits Highlights
The following summarizes recurring compensation and benefits themes identified from responses generated by popular LLMs to common candidate questions about Mirum Pharmaceuticals and has not been reviewed or approved by Mirum Pharmaceuticals.
-
Equity Value & Accessibility — Equity grants to new hires and an employee stock purchase plan make ownership more accessible and can boost total rewards when performance is strong. Public disclosures highlight frequent option/RSU inducements.
-
Healthcare Strength — Comprehensive medical, dental, and vision coverage is employer-paid for employees, with added life, disability, and EAP support. This combination reduces financial burden and enhances overall wellbeing.
-
Leave & Time Off Breadth — A broad time-off program includes multiple paid company holidays, a year-end shutdown, accrued vacation, and paid parental leave. This breadth provides additional rest periods beyond standard vacation.
Mirum Pharmaceuticals Insights
What We Do
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. Mirum’s approved medication is LIVMARLI® (maralixibat) oral solution which is approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older. Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. Maralixibat (LIVMARLI), an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the MARCH Phase 3 study for progressive familial intrahepatic cholestasis (PFIC) and the EMBARK Phase 2b study for patients with biliary atresia. In addition, Mirum has an expanded access program open in Canada, Australia, the UK and several countries in Europe for eligible patients with Alagille syndrome. Mirum has submitted a Marketing Authorization Application to the European Medicines Agency for maralixibat for the treatment of cholestatic liver disease in patients with Alagille syndrome. Mirum’s second investigational treatment, volixibat, also an oral IBAT inhibitor, is being evaluated in three potentially registrational studies including the OHANA Phase 2b study for pregnant women with intrahepatic cholestasis of pregnancy, VISTAS Phase 2b study for adults with primary sclerosing cholangitis, and the VANTAGE Phase 2b study for primary biliary cholangitis.
